Since tivantinib has previously been suggested to elicit anticancer activity in NSCLC through disruption of microtubule dynamics29,30, we further evaluated the relative contribution that inhibition of MET, GSK3 or microtubule polymerization plays in tivantinib’s mechanism of action in these cells. The gene discussed is MET; the disease is non-small cell lung carcinoma.